Capricor's Duchenne therapy faces likely FDA denial
Capricor Therapeutics is working to avert a negative FDA decision on its cell therapy for Duchenne muscular dystrophy. The company is seeking to address concerns before the agency issues a final ruling.
Related stories
Capricor to submit supplemental data to FDA for Duchenne therapy after advisory panel rejection · Drug development
Capricor's Duchenne therapy faces delayed FDA decision due to additional data review · Drug development
Fatal outcome surfaces in Chinese gene therapy study, raising transparency concerns · Drug development
Opinion: Small study choices can decide Duchenne drug's fate · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection.” Browse more stories.